CSV May 15, 2022 through May 15, 2024 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE	ADDITIONAL R	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR INJECTION	EQUIREMENTS/*USP Reference Standards <11>*							Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.13 to: (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octah

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ydro-3,5,10,12, 12a-pentahydro xy-6-methyl-1,1 1-dioxo-2-napht hacenecarboxa mide hydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.90
PROMETHAZINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	26-Aug-2022	1-Sep-2022	*NA*	*NA*	Change **System suitability solution**: 5 µg/mL each of USP Promethazine Hydrochloride RS and USP Promethazine Related Compound B RS from the *Standard stock solution* and *System suitability stock solution*, respectively **Standard solution**: 5

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								µg/mL of USP Promethazine Hydrochloride RS from the *Standard stock solution* **Sensitivity solution**: 0.25 µg/mL of USP Promethazine Hydrochloride RS from the *Standard solution* to: **System suitability solution**: 5 µg/mL each of USP Promethazine Hydrochloride RS and USP Promethazine Related Compound B RS from the *Standard stock solution* and *System*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability stock solution, respectively, in *Diluent* **Standard solution**: 5 µg/mL of USP Promethazine Hydrochloride RS from the *Standard stock solution* in *Diluent* **Sensitivity solution**: 0.25 µg/mL of USP Promethazine Hydrochloride RS from the *Standard solution* in *Diluent*
NALOXONE HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Limit of Naloxone Related Compound D*: Delete **Sensitivity solution**: 1.25 µg/mL of USP

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Naloxone Related Compound D RS in 0.1 N hydrochloric acid AND In *System suitability*/*Samples*: Delete *Sensitivity solution*, AND In *System suitability*/*Suitability requirements*: Delete **Signal-to-noise ratio**: NLT 10, *Sensitivity solution*
METARAMINOL BITARTRATE	SPECIFIC TESTS/*Content of Tartaric Acid*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Result = {[(V_S?V_B) × N × F]/2 × W} × 100 to: Result = {[(*V*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_S$?V_B) × N × F]/(2 × W)} × 100
ISOFLURANE	IM PURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change Result = (r_U/r_S) × C_S × (1/F) to: Result = (r_U/r_S) × C_F × (1/F) AND Change C_S = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%) to: C_F = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%)
REAGENTS AND	*Reagent S*	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	Change 127-65-1

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
REFERENCE TABLES	*pec ification s/ Tosylchloramid e Sodium*							to: 7080-50-4
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 8*/*Tolerances*: Change The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance Table 1*. to: The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SECOBARBITAL SODIUM	OTHER REQUIREMENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	<711>, *Acceptance Table 2*. Change Where the label states that Seco barbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. Where the label states that Secobarbital Sodium must be subjected to further processing during the preparation of injectable dosage forms, it meets the requirements

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for *Bacterial endotoxins* under *Secobarbital Sodium for Injection*. to: Where the label states that Secobarbital Sodium is sterile, it meets the requirements for *Sterility Tests* ?71? and the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>. Where the label states that Secobarbital

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sodium must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins is not more than 0.9 USP Endotoxin Units per mg of secobarbital sodium tested per *Bacterial Endotoxins Test* <85>.
AMMONIUM GLYCYRRHIZATE	ASSAY/*Content of Ammonium 18?- and 18?-Glycyrrhizate*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Analysis*: Change $M_{W(Salt)}$ = molecular weight of ammonium glycyrrhizate, 840.08 g/mol $M_{W(Acid)}$ = molecular weight of

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								glycyrrhizic acid, 821.59 g/mol to: $M_{W(Salt)}$ = molecular weight of ammonium glycyrrhizate, 839.97 g/mol $M_{W(Acid)}$ = molecular weight of glycyrrhizic acid, 822.94 g/mol
LANSOPRAZOLE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	Delete **Blank**: Methanol and *Diluent* (1:9)
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *System suitability*: Change **Samples**: *System suitability solution*, *Standard solution A*, and *Standard*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution B to: **Samples**: *System suitability solution* and *Standard solution A* AND In *Analysis*: Change **Samples**: *Mobile phase*, *Standard solution A*, and *Sample solution* Chromatograph the *Standard solution* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: **Samples**: *Mobile phase*, *Standard*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution A, *Standard solution B*, and *Sample solution* Chromatograph *Standard solution B* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection.
ERYTHROMYCIN DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 1*: Change **Buffer stage Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*) to: **Buffer stage Medium**: 0.05 M pH 6.8 phosphate

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*); 900 mL
OSELTAMIVIR PHOSPHATE	IMPURITIES/*Organic Impurities/Procedure 3: Limit Of Tributyl Phosphine Oxide*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In *System suitability/Suitability requirements/Relative standard deviation*: Change NMT 10.0% for the tributyl phosphine oxide and osteltamivir phosphate peaks to: NMT 10.0% for the tributyl phosphine oxide and oseltamivir phosphate peaks
DEXTROMETH	*Assay*	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORPHAN HYDROBROMIDE ORAL SOLUTION								*Chromatographic system* and *Procedure*: Change *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS, on the anhydrous basis, in the *Standard preparation*; to: *C* is the concentration, in mg per mL, of USP Dextromethorphan Hydrobromide RS in the *Standard preparation*;
COLOR AND ACHROMICITY	METHOD II: INSTRUMENTAL (QUANTITATIVE) ASSESSMENT OF COLOR	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Table 5*: Change Sum 98.809 100.000 107.307 White point

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	AND COLOR MATCHES							98.811 100.000 107.304 to: Sum 94.809 100.000 107.307 White point 94.811 100.000 107.304
METOLAZONE	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities/ Chromatographic system/Column*: Change 4.6-mm × 25-cm; 5-µm packing 1 to: 4.6-mm × 25-cm; 5-µm packing L1
BOTANICAL EXTRACTS	PREPARATIONS	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *General Pharmacopeial Requirements/Pesticide Residues*: Change

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								where *L* is the limit in the original article as listed in *Table 4* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin <561>*) to: where *L* is the limit in the original article as listed in *Table 5* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin <561>*)
POWDERED FORSKOHLII EXTRACT	COMPOSITION */Content of Forskolin*	*USPNF Online*	Online	29-Jul-2022	1-Aug-2022	*NA*	*NA*	In *Chromatographic system*: Change Column: 4.6-mm × 25-cm; 5-µm, 100 Å

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Column: 4.6-mm × 25-cm; 5-µm, 100 Å; packing L1
DOXORUBICIN HYDROCHLORIDE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
MESO-ZEAXANTHIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	In USP *meso*-Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to: (3*R*,3?*S*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-Zeaxanthin.
LEVORPHANOL TARTRATE TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units* ?905?	*USPNF Online*	Online	31-Mar-2023	1-Aug-2023	*NA*	*NA*	In *Sample solution*: Change Nominally about 80 ug/mL of levorphanol tartrate in *Diluent* prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in *Diluent* prepared as follows.
ATORVASTATIN CALCIUM TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In *Test 1*, *Test 3*, *Test 4*, *Test 5*, and *Test 6*/*Analysis*: Change M_{r1} = molecular weight of atorvastatin, 558.64 M_{r2} = molecular weight of atorvastatin

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								calcium, 1155.34 to: M_{r1} = molecular weight of atorvastatin, 558.65 M_{r2} = molecular weight of atorvastatin calcium, 1155.36
OCTOCRYLENE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A./Acceptance criteria*: Change NMT 3.0%, calculated on the as-is basis to: Absorptivities, calculated on the as-is basis, do not differ by more than 3.0%.
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution ?711?/Test 2/Acid stage*: Change **Acid stage standard**

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: (*L*/10) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet to: **Acid stage standard solution:** (*L*/10000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Acid stage medium*, where *L* is the label claim in mg/Tablet AND In *Dissolution* <711>/*Test 2*/*Buffer stage*:

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change **Buffer stage standard solution:** (*L*/1000) of USP Pantoprazole Sodium RS where *L* is the label claim in mg/Tablet to: **Buffer stage standard solution:** (*L*/1000) mg/mL of USP Pantoprazole Sodium RS from the *Standard stock solution* in *Buffer stage medium*, where *L* is the label claim in mg/Tablet
BROMPHENIRAMINE MALEATE	SPECIFIC TESTS	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	Change **Optical Rotation** ?781? to:

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXYCYCLINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	**Optical Rotation**, *Angular Rotation* ?781A? In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, monohydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.13 to:

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROMETHAZINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	26-Aug-2022	1-Sep-2022	*NA*	*NA*	(4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride. $C_{22}H_{24}N_2O_8 \cdot HCl$ 480.90 Change **System suitability solution**: 5 µg/mL each of USP Promethazine Hydrochloride RS and USP Promethazine Related Compound B RS from the *Standard stock solution* and *System*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability stock solution, respectively **Standard solution**: 5 µg/mL of USP Promethazine Hydrochloride RS from the *Standard stock solution* **Sensitivity solution**: 0.25 µg/mL of USP Promethazine Hydrochloride RS from the *Standard solution* to: **System suitability solution**: 5 µg/mL each of USP Promethazine Hydrochloride RS and USP Promethazine Related

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compound B RS from the *Standard stock solution* and *System suitability stock solution*, respectively, in *Diluent* **Standard solution**: 5 µg/mL of USP Promethazine Hydrochloride RS from the *Standard stock solution* in *Diluent* **Sensitivity solution**: 0.25 µg/mL of USP Promethazine Hydrochloride RS from the *Standard solution* in *Diluent*
FELODIPINE	IM PURITIES/*Organic*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Buffer**, **Mobile phase**, **System**

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							**suitability solution**, **Standard solutio n**, **Sample solution**, and **Chromatograp hic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solutio n**, **Sample solution**, and **Chromatograp hic system**: Proceed as directed in the *Assay*, and use 40 µL injection volume for the *Sensitivity solution*.
METARAMINO	ADDITIONAL R	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
L BITARTRATE	EQUIREMENTS/*USP Reference Standards ?11?*							Metaraminol Enantiomer RS: Change 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol. $C_9H_{13}NO_2$ 167.21 to: 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol D-tartrate. $C_9H_{13}NO_2$? $C_4H_6O_6$ 317.29
BUPIVACAINE HYDROCHLORIDE INJECTION	ASSAY/*Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Chromatographic system*/*Column*: Change 4-mm × 30-cm; packing L1 to: 3.9-mm × 30-cm; packing L1 AND In *System suitability*: Change

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								[Note—The relative retention times for bupivacaine hydrochloride and dibutyl phthalate are about 1.0 and 1.2, respectively.] to: [Note—The relative retention times for bupivacaine and dibutyl phthalate are about 1.0 and 1.2, respectively.] AND In System suitability/Suitability requirements: Change **Resolution**: NLT 2.0 between bupivacaine hydrochloride and dibutyl

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phthalate **Relative standard deviation**: NMT 1.0% for the ratio of bupivacaine to the internal standard from three replicate injections to: **Resolution**: NLT 2.0 between bupivacaine and dibutyl phthalate **Relative standard deviation**: NMT 1.0% for the peak response ratio of bupivacaine to the internal standard from three replicate injections
TRIAZOLAM	PERFORMANC	*USPNF Online*	Online	28-Jul-2023	1-Aug-2023	*NA*	*NA*	In *Standard*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	E TESTS/ *Dissolution* ?711?							*solution*: Change Tablet/mg to: mg/Tablet
TAMSULOSIN HYDROCHLORIDE CAPSULES	IMPURITIES	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Organic Impurities*/*System suitability*: Change **Sample:** *Standard solution* [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80, respectively.] **Suitability requirements** **Tailing factor:** NMT 2.0

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Relative standard deviation: NMT 5.0% **Signal-to-noise ratio:** NLT 10 to: **Samples:** *Standard solution* and *Sensitivity solution* [Note—The relative retention times for methoxy tamsulosin, tamsulosin, ethoxyphenoxy ethyl bromide, and desethoxy tamsulosin are 0.73, 1.00, 1.80, and 2.80, respectively.] **Suitability requirements** **Tailing factor:** NMT 2.0, *Standard*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution **Relative standard deviation:** NMT 5.0%, *Standard solution* **Signal-to-noise ratio:** NLT 10, *Sensitivity solution*
AMOXICILLIN ORAL SUSPENSION	IDENTIFICATION	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	Change Shake a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. The solution responds to the *Identification* test under *Amoxicillin*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Capsules. to: Prepare a test solution by shaking a portion of Oral Suspension with a mixture of acetone and 0.1 N hydrochloric acid (4:1) to obtain a solution containing about 1 mg of amoxicillin per mL. Prepare a Standard solution of USP Amoxicillin RS in 0.1 N hydrochloric acid containing 1 mg per mL. Use within 10 minutes after preparation. Apply separately 5 µL of each solution

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								on a thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica gel mixture (see *Chromatography* ?621?). Place the plate in a suitable chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol, chloroform, water, and pyridine (90:80:30:10). When the solvent front has moved about three-fourths of the length of the plate, remove

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the plate from the chamber, and dry with warm air for 10 minutes. Locate the spots on the plate by spraying lightly with a solution of ninhydrin in alcohol containing 3 mg per mL, and dry at 110° for 15 minutes: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.
PACKAGING AND STORAGE REQUIREMENTS	GENERAL *Packaging Definitions*	*Second Supplement to USP43–NF38*	Online	26-Mar-2021	1-Dec-2025	*NA*	*NA*	In *Light-resistant container*: Change ?661.2?, *Functionality, Spectral*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Transmission Requirements for Light-Resistant Components and Systems. to: ?661.2?, *Functionality Test Method, Spectral Transmission Requirements for Light-Resistant Components and Systems*.
AMMONIUM GLYCYRRHIZATE	SPECIFIC TESTS	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Optical Rotation, Specific Rotation ?781?*: Change ?781? to: ?781S? AND Change **Acceptance criteria**: +49.0 to +55.0 on the anhydrous

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								basis to: **Acceptance criteria**: +49.0° to +55.0° on the anhydrous basis
CEFTIOFUR HYDROCHLORIDE	ASSAY/ *Procedure*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of ceftiofur ($C_{19}H_{17}N_5O_7S_3$) in the portion of Ceftiofur Hydrochloride taken: Result = $(r_U/r_S) \times (C_S/C_U) \times P \times 100$ to: Calculate the quantity, in µg/mg, of ceftiofur ($C_{19}H_{17}N_5O_7S_3$) in the portion of Ceftiofur Hydrochloride taken: Result = (*r*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U/r_S$) × (C_S/C_U) × *P*
PALONOSETRON HYDROCHLORIDE	IMPURITIES	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *Limit of Unspecified Impurities*: Change **Mobile phase** and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Mobile phase**, **Standard stock solution**, and **Chromatographic system**: Proceed as directed in the *Assay*.
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Identification*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Proceed as directed in the *Identification* test under *Erythromycin Ethylsuccinate Oral Suspension*,

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								beginning with “Prepare a Standard solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel mixture, and allow to dry.

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Place the plate in an unlined chromatographic chamber, and develop the chromatograms in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of dehydrated alcohol, *p*-methoxybenzaldehyde, and sulfuric acid (90:5:5). Heat

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the plate at 100° for 10 minutes, and examine the chromatograms, in which the erythromycin and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to those obtained from the Standard solution.
CALCIUM ASCORBATE	IDENTIFICATION/*A.*	*USPNF Online*	Online	26-May-2023	1-Aug-2023	*NA*	*NA*	Change Characteristic emission lines for calcium at 184.0, 315.9, and 317.9 nm from the *Sample solution* correspond to those from the

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution, as obtained in the *Assay*. to: Characteristic emission lines for calcium at 184.0, 315.9, and 317.9 nm from the *Sample solution* correspond to those from the *Standard solution*, as obtained in the *Content of Calcium*.
AMANTADINE HYDROCHLORIDE	IDENTIFICATION	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *A*.: Change *Spectroscopic Identification Tests* ?197?, *Infrared Spectroscopy*: 197A, 197K, and 197S to: *Spectroscopic Identification Tests* ?197?,

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Infrared Spectroscopy: 197A, 197K, or 197S **Procedure for 197S**
MEASUREMENT OF STRUCTURAL STRENGTH OF SEMISOLIDS BY PENETROMETRY	APPARATUS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Figure 2*: Change 66±0.25 Ø to: 65±0.25 Ø
PROPOFOL	ASSAY	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Procedure 2*/*Mobile phase*: Change Hexane, acetonitrile, and alcohol (990: 7.5: 1) to: Hexane, acetonitrile, and alcohol, absolute (990: 7.5: 1)
NANDROLONE DECANOATE	ASSAY/ *Procedure*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of Nandrolone

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FORSKOHLII	COMPOSITION /*Content of Forskolin*	*USPNF Online*	Online	29-Jul-2022	1-Aug-2022	*NA*	*NA*	Decanoate ($C_{28}H_{44}O_3$) in the portion of Nandrolone Decanoate taken: to: Calculate the percentage of nandrolone decanoate ($C_{28}H_{44}O_3$) in the portion of Nandrolone Decanoate taken: In *Chromatographic system*: Change Column: 4.6-mm × 25-cm; 5-µm, 100 Å to: Column: 4.6-mm × 25-cm; 5-µm, 100 Å; packing L1
DOXORUBICIN	ASSAY/	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE INJECTION	*Procedure*							Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
AZTEC MARIGOLD ZEAXANTHIN EXTRACT	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 2*/*Analysis*: Change C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Ethinyl Estradiol RS (ug/mL) in the *Standard solution* to: C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (µg/mL) in the *Standard solution*
ATORVASTATIN CALCIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards* ?11?	*USPNF Online*	Online	30-Jun-2023	1-Jul-2023	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change 1155.34 to: 1155.36
ZIPRASIDONE CAPSULES	ASSAY	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Procedure/Analysis*: Change 449.40 to: 449.39
SODIUM	ADDITIONAL R	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP*

Monograph Title	Section	Source Publication	Page Number Sort ascending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SALICYLATE	EQUIREMENTS							*Reference Standards* ?11?: Add USP Phenol RS

Pagination

- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Next page Next ›
- Last page Last »